Condition: Heart Failure · Heart Diseases · Cardiovascular Diseases · Sponsor: Abbott Medical Devices
The purpose of TEAM-HF IDE clinical trial is to evaluate safety and effectiveness of the HeartMate 3 LVAS compared to guideline directed medical therapy (GDMT) in a population of ambulatory advanced heart failure patients who are not dependent on intravenous inotrope.
This description comes directly from the study's public registry record.
Nourdine Chakouri, PhD · 925-989-5982 · nourdine.chakouri@abbott.com
Always discuss trial participation with your own doctor first.
| Banner-University Medical Center Phoenix | Phoenix, Arizona, United States | Recruiting |
| Baptist Health Medical Center | Little Rock, Arkansas, United States | Recruiting |
| Sutter Medical Center | Sacramento, California, United States | Recruiting |
| University of California at San Francisco | San Francisco, California, United States | Recruiting |
| Washington Hospital Center | Washington D.C., District of Columbia, United States | Recruiting |
| Shands at the University of Florida | Gainesville, Florida, United States | Recruiting |
| Cleveland Clinic Florida | Weston, Florida, United States | Recruiting |
| Piedmont Heart Institute | Atlanta, Georgia, United States | Recruiting |
| Piedmont Augusta Hospital | Augusta, Georgia, United States | Recruiting |
| WellStar Kennestone Hospital | Marietta, Georgia, United States | Recruiting |
| University of Chicago | Chicago, Illinois, United States | Recruiting |
| Advocate Health & Hospitals Corporation | Oakbrook Terrace, Illinois, United States | Recruiting |
+ 56 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06526195